U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07716332) titled 'Apixaban Versus Enoxaparin for Postpartum Venous Thromboembolism Prophylaxis' on March 22.
Brief Summary: The purpose of this study is to compare the use of oral apixaban to subcutaneous enoxaparin for venous thromboembolism (VTE) prophylaxis in postpartum women at high risk for VTE. The primary goal is to evaluate medication adherence rates and patient satisfaction with the treatment.
Study Start Date: July 01
Study Type: INTERVENTIONAL
Condition:
Postpartum
DVT Prophylaxis
Intervention:
DRUG: Apixaban
Apixaban. 2.5 mg administered orally twice a day
DRUG: Enoxaparin
Enoxaparin 40 mg (or 60 mg for weight > 91 kg) administe...